{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-027754","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.284733+00:00","generated_at":"2026-06-24T05:10:25.171154+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"REGENXBIO Q2 net loss $68.2M, revenues up 48%; RGX-314 BLA on track for 2024","bullets":["Net loss $68.2M ($1.58/share) vs $57.6M ($1.36) in Q2 2021; revenues $32.6M up 48% YoY.","Cash and marketable securities $682M (down from $849M Dec 2021); runway into 2025.","RGX-314 (wet AMD/DR) on track for BLA in 2024; pivotal trials enrolling; AAVIATE Cohort 5 complete; ALTITUDE enrollment complete.","RGX-121: intend to file BLA in 2024 via accelerated approval; pivotal CAMPSIITE trial active enrolling up to 10 patients.","RGX-202 first patient dosing expected in first half 2023; NAV licensee Zolgensma Q2 sales $379M."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-027754","json":"https://secwatch.observer/filing/0001564590-22-027754.json","markdown":"https://secwatch.observer/filing/0001564590-22-027754.md","text":"https://secwatch.observer/filing/0001564590-22-027754.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000156459022027754/0001564590-22-027754-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000156459022027754/rgnx-8k_20220803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:10:25.171154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}